Careers Contact Locations

OPKO Health, Inc.

  • Home
  • Who We Are
    • Our Vision
    • Our History
    • Our Leadership
  • What We Do
    • Overview
    • Our Products
    • Our Solutions
    • Our Technology
    • Our Research
    • Our Diagnostics
  • News & Media
    • Press Releases
    • Announcements
    • Events
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact
  • Locations

OPKO Acquires ModeX Therapeutics

Learn More

Press Releases

News & Media

News & Media

  • Press Releases
  • Announcements
  • Events
  • Presentations

OPKO Health to Present at the 2022 Jefferies Healthcare Conference

Jun 2, 2022

OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

May 9, 2022

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

May 9, 2022

OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

May 5, 2022

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

May 2, 2022

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

Feb 24, 2022

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

Feb 17, 2022

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

Feb 15, 2022

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

Feb 3, 2022

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

Jan 21, 2022
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...47
Next
© 2022 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of Use Sitemap